AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tetratherix Ltd

6.300

+0.3806.42%

Volume:11.75K

Turnover:71.95K

Market Cap:333.46M

PE:-34.28

High:6.300

Open:6.100

Low:6.100

Close:5.920

52wk High:8.080

52wk Low:3.090

Shares:52.93M

Float Shares:16.15M

Volume Ratio:0.47

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.184

EPS(LYR):-0.184

ROE:-31.08%

ROA:-14.05%

PB:10.19

PE(LYR):-34.28

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Tetratherix Completes First Preclinical Performance Study for Eye Surgery Device

MT Newswires Live

Tetratherix Begins Tetramatrix Product Revenue With First US Shipment

MT Newswires Live

Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise

MT Newswires Live

Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/TTX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","market":"AU","secType":"STK","nameCN":"Tetratherix Ltd","latestPrice":6.3,"timestamp":1790748720000,"preClose":5.92,"halted":0,"volume":11754,"delay":0,"changeRate":0.06418918918918917,"nameEN":"Tetratherix Ltd","floatShares":16151799,"shares":52929483,"eps":-0.1838,"marketStatus":"Not Yet Opened","change":0.38,"latestTime":"09-30 16:12:00 AEST","open":6.1,"high":6.3,"low":6.1,"amount":71949,"amplitude":0.033784,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1838,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":0,"adr":0,"listingDate":1751119200000,"exchange":"ASX","adjPreClose":5.92,"openAndCloseTimeList":[[1790726400000,1790748000000]],"volumeRatio":0.4662805473382436,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TTX.AU","preClose":6.3,"auctionPrice":6.28,"auctionVolume":48,"auctionTime":1790802291192,"referenceTime":1790764203089,"auction":1,"marketStatus":"盘前竞价","timestamp":1790802291192}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","floatShares":16151799,"roa":"-14.05%","roe":"-31.08%","lyrEps":-0.1838,"volumeRatio":0.4662805473382436,"shares":52929483,"dividePrice":0,"high":6.3,"amplitude":0.033784,"preClose":5.92,"low":6.1,"week52Low":3.09,"pbRate":"10.19","psRate":"86.35","week52High":8.08,"institutionHeld":0,"latestPrice":6.3,"eps":-0.1838,"divideRate":0,"volume":11754,"delay":0,"ttmEps":-0.1838,"open":6.1,"prevYearClose":3.28,"prevWeekClose":6.2,"prevMonthClose":6.3,"prevQuarterClose":6.3,"fiveDayClose":6.37,"twentyDayClose":7.2,"sixtyDayClose":6.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667558679","title":"Tetratherix Completes First Preclinical Performance Study for Eye Surgery Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2667558679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667558679?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:25","pubTimestamp":1789525553,"startTime":"0","endTime":"0","summary":"Tetratherix  said it completed its first preclinical performance study for its ophthalmic viscosurgical device, Optimatrix, in cataract surgery with a recognized animal model, according to a Wednesday Australian bourse filing.Animals underwent a cataract operation in both eyes, on the same day and by the same surgeon. In one eye, Optimatrix was used and then left in place. In the other eye, a sham procedure was performed using a salt solution, which was removed at the end of the procedure.With Optimatrix, even with the product remaining inside the eye, intraocular eye pressure was back at pre-operative levels within six hours and did not rise again by 48 hours. The surgical device was developed from Tetramatrix's platform polymer.Two new patents were lodged covering the composition of matter and the use application for cataract surgery.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663618023","title":"Tetratherix Begins Tetramatrix Product Revenue With First US Shipment","url":"https://stock-news.laohu8.com/highlight/detail?id=2663618023","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663618023?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:50","pubTimestamp":1788137454,"startTime":"0","endTime":"0","summary":"Tetratherix  made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733736","title":"Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653733736?lang=en_us&edition=fundamental","pubTime":"2026-07-22 12:00","pubTimestamp":1784692834,"startTime":"0","endTime":"0","summary":"Tetratherix  received its first license fee revenue of $3 million in the June quarter as part of an exclusive research and development agreement with US consumer health group Superpower, according to a Wednesday filing with the Australian bourse.The fee revenue, combined with a net AU$14.7 million from a placement in May, left the company with a \"strong cash position\" of AU$34.4 million as of June 30, per the filing.The company closed the March quarter with AU$19.2 million of cash on hand, a previous filing showed.Tetratherix said it saw AU$19.3 million of cash inflows in the three months through June, bringing the total to AU$21.9 million for the full 2026 fiscal year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645300206","title":"Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2645300206","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645300206?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:57","pubTimestamp":1782187060,"startTime":"0","endTime":"0","summary":"Tetratherix  said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLF.AU","DACE.AU","IOZ.AU","IMLC.AU","XJO.AU","EIGA.AU","ZYAU.AU","BEAR.AU","STW.AU","XAO.AU","BK7067","QRE.AU","E200.AU","IIGF.AU","IISV.AU","GEAR.AU","QFN.AU","BBOZ.AU","XKO.AU","VAP.AU","OZR.AU","VAS.AU","OZF.AU","GIVE.AU","TTX.AU","JYNT","BK4185"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TTX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}